DOI:
10.1055/s-00000094
Zeitschrift für Gastroenterologie
LinksClose Window
References
Asselah T, Pol S, Hezode C. et al.
Efficacy and Safety of Elbasvir/Grazoprevir for 8 or 12 Weeks in Participants with Hepatitis C Virus Genotype 4 Infection.
Hepatology 2018;
68: 385a-385a
Search in:
We do not assume any responsibility for the contents of the web pages of other providers.